Concierge Gynecology’s Six-Figure Wait List: Inside the Economics of ‘Sexspan’ Medicine

A New Yorker profile of Dr. Sally Greenwald, a 40-year-old assistant clinical professor at Stanford who runs a concierge gynecology practice, describes a business model that has become familiar in the Bay Area wellness economy: exclusivity priced into a wait list, revenue detached from insurance reimbursement, and a customer base drawn almost entirely from the top of the wealth distribution.

New patients pay tens of thousands of dollars a year to join Greenwald's practice, according to the report, and access is gated by a wait list that has grown alongside her profile among high-net-worth clients. That structure, cash-pay concierge medicine sold to a self-selecting affluent cohort, is the relevant fact for anyone reading this as a market story rather than a health one.

The unit economics of a wait list

Concierge medicine inverts the standard clinical revenue model. Instead of billing insurers per procedure at negotiated rates, the practice collects an annual membership fee from a capped roster of patients. Greenwald's reported pricing, tens of thousands of dollars per patient per year, means a panel of even a few hundred members produces recurring revenue in the millions before any procedure-level billing.

The wait list is not incidental. In subscription-style service businesses, a backlog functions as both a pricing signal and a demand buffer. It allows the operator to raise fees against confirmed excess demand and to keep the customer base concentrated among those least sensitive to price. The New Yorker notes that some patients found Greenwald through private gatherings, including one hosted by Priscilla Chan Zuckerberg, a distribution channel that costs nothing and pre-qualifies buyers by proximity to wealth.

The adjacent monetization layers

The practice is not the only revenue line. Greenwald received a seven-figure book advance from HarperCollins after what the report describes as a competitive auction, with Sheryl Sandberg writing a blurb. A seven-figure trade advance is unusual and signals that the publisher is underwriting a personal brand with an established affluent audience, not just a manuscript.

This is the same playbook that longevity-focused practitioners such as Peter Attia and Andrew Huberman, both named in the report as reference points, have run on the male side of the market: clinical credibility converted into media assets, which in turn feed demand back into the higher-margin service business. The book advance, the speaking appearances, and the concierge fees are complementary rather than separate.

What the filing would need to show

The report is candid about a distinction that matters for anyone assessing the durability of the model. Greenwald herself draws a line between recommendations backed by randomized controlled trials and those she describes as belonging to the "woo-woo" world of concierge medicine, based on anecdotal evidence and observational studies. She frames some of her hormone-therapy approach on "biological plausibility" rather than completed trial data, and she has said she will revise her views "when the data come out to prove the opposite."

For a business, that candor is also the risk. Revenue built on interventions ahead of the evidence base carries regulatory and reputational exposure that a fee-for-service, insurance-reimbursed practice would not. The customer base described here is explicitly impatient, unwilling to wait a decade for trial results, which supports pricing power in the near term but concentrates the practice's fortunes in a demographic that can exit as quickly as it entered.

Greenwald reportedly once referred to the practice, jokingly, as the Billionaires' Vagina Club before dropping the name after patients objected. The label captured the actual customer segmentation better than any marketing deck: a narrow, high-value cohort whose spending is uncorrelated with insurance policy or macro conditions.

The Asia read-across

The concierge longevity model is not confined to California. Singapore, Hong Kong, and Bangkok have built substantial private wellness and executive-health industries serving expatriate and regional high-net-worth clients, often on the same cash-pay, membership-driven basis. The economics travel well precisely because they depend on wealth concentration and a willingness to pay out of pocket, conditions present across much of the region's private-medicine market. The women-focused angle, hormone and menopause care marketed as longevity rather than treatment, remains comparatively underdeveloped in Asia, which is why the U.S. blueprint is worth watching for operators considering the segment.

Whether Greenwald's specific interventions hold up against future trial data is a clinical question. The business question is narrower and already answered by the wait list: at this price point, in this customer base, demand exceeds supply.